Headlands Research Changes Hands: Does Consolidation Make Sites Better?
Published November 2026 — THL Partners agreed in August 2025 to buy Headlands Research from KKR, moving one of the largest site networks from one private equity owner to another. Buyers say scale brings consistency. Critics say it brings risk. Sponsors need a way to tell, site by site.
One Network, Two Owners, and an Open Question
On August 14, 2025, THL Partners announced a definitive agreement to acquire Headlands Research from funds managed by KKR. KKR founded Headlands in 2018. The price was not disclosed; Reuters, citing unnamed sources, put it at about $600 million, a figure that has not been confirmed.
The sale of a site network from one investment firm to another is now an ordinary event in clinical research. This case study sets out the arguments made for and against that trend and what they mean for a sponsor choosing sites.
Key Findings
The announcement states that Headlands has completed more than 5,000 clinical trials since its founding in 2018.
THL describes Headlands as having more than 20 wholly owned sites across the United States and Canada, focused on CNS, vaccines and infectious disease, and metabolic conditions.
Reported by Reuters from unnamed sources and relayed by trade press. Neither party has confirmed it.
A 2022 KFF Health News investigation found that 11 of the 25 largest private equity investors in health care had bought stakes in clinical research companies.
The Case For and Against
Both sides of the argument are on the public record.
The Buyer's Case
THL has said it will fund expansion and build technology and centralized infrastructure. Its stated view is that sponsors prefer a smaller number of scaled partners to a fragmented base of individual clinics. THL principal Peter McClelland described Headlands as providing the operational backbone to help sponsors get therapies to patients faster.
The Record So Far
Scale does not guarantee stability. KFF Health News reported that in September 2022 Headlands closed its Houston and Lake Charles sites and stopped taking new research at its McAllen site. The chief executive at the time attributed this to difficulty finding experienced, highly qualified staff.
The Critics' Case
In the same report, Harvard's Dr. Aaron Kesselheim called private equity involvement in trials concerning, pointing to informed consent and privacy. The Private Equity Stakeholder Project said in November 2025 that private equity expansion into clinical trials is accelerating. In April 2026, The Capitol Forum reported that the trend could raise antitrust and corporate practice of medicine questions.
What Is Missing
None of these sources offers site-level evidence that consolidation improves or harms trial performance. We found no peer-reviewed study of private equity ownership of trial sites. The argument is being conducted largely without data.
What This Means for Sponsors
A sponsor does not select a network. It selects the sites that will run its study.
Sites inside the same network can differ widely in staff, investigators, and results. Ask for performance at the level of the individual site for the indication in question.
After a change of ownership, check whether the investigators and coordinators who earned the site's record are still there, and whether any locations have closed or paused.
Network sites, independent sites, and academic centers should be compared on the same measures. Otherwise the choice rests on reputation and scale.
Conclusions
The sale of Headlands shows that site networks have become assets that are bought, built up, and sold again. That may bring investment in infrastructure, and it may bring disruption. The public evidence does not settle which.
For sponsors, the practical answer is to look past ownership. What matters for a study is how each site performs now, and whether that can be verified.
Site-Level Evidence, Whoever Owns the Site
SiteScore™ scores each site individually, on the same 0–100 scale, whether it belongs to a network, an academic center, or no one but its founders. Sponsors can search scored sites, build shortlists, and compare candidates side by side.
A Validated Score is checked against the site's own documents and re-run through the year, so changes that follow a change of ownership, in staffing, enrollment, or compliance, show up in the score.
This industry case study is based on published announcements and industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative. Companies named are not Clinitiative clients unless stated.
- THL: THL announces agreement to acquire Headlands Research from KKR (August 14, 2025)
- THL: Why we invested in Headlands Research
- Clinical Trials Arena: THL to acquire clinical trial network Headlands Research
- KFF Health News: Clinical trials are a new private equity business (December 2, 2022)
- Private Equity Stakeholder Project: Private equity moves into clinical trials (November 24, 2025)
- The Capitol Forum: Private equity investment in clinical trial sites raises potential antitrust, CPOM concerns (April 17, 2026)
See How SiteScore™ Works
Standardized, document-verified scoring for clinical research sites, used by sponsors, sites, and investors.